πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,641 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12228572

Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-inf

The First Hospital of China Medical University Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12220455

Coronavirus vaccine compositions and methods

ARCTURUS THERAPEUTICS, INC. Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12213989

Use of maribavir in treatment regimens

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12208093

Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)

THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12210017

Peptides representing epitopes from filoviruses

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12201658

Viral gene therapy as treatment for cholesterol storage disease or disorder

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186363

Compositions and methods for dengue virus chimeric constructions in vaccines

The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12188039

Recombinant adeno-associated viral vector for gene delivery

The Board of Regents of the University of Texas System Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186342

Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, I

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12187779

Anti-human papillomavirus 16 E6 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12173029

Antiviral prodrugs, pharmaceutical formulations, and methods

The Regents of the University of California Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12172038

Anti-coronavirus antibodies and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Svcs. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12173307

Methods for the purification of viral vectors

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12173289

Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12168013

Antiviral prodrugs and nanoformulations thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12168675

Virus-like particles and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12162857

Antiviral compounds

Enanta Pharmaceuticals, Inc. Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12156908

Virus like nanoparticle compositions and methods thereof

Regents of the University of Minnesota Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12152067

Human antibodies to ebola virus glycoprotein

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12145941

Heterocyclic antiviral agents

Enanta Pharmaceuticals, Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12138243

Antiviral use of FABP4 modulating compounds

CRESCENTA BIOSCIENCES Β· Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12129476

Methods for measuring the potency of AADC viral vectors

VOYAGER THERAPEUTICS, INC. Β· Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12121503

Antiviral treatments

BioCryst Pharmaceuticals, Inc. Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12121567

Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase usin

Regents of the University of Minnesota Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted